Company / EPS (Diluted)
Trevi Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.47
FY2024
5-year range
-$1.49 / -$0.29
FY2021-FY2024
Trend
-62.1%
vs FY2023
Sector context
#67 of 204
Health Care
What the data says
At $-0.47, Trevi Therapeutics, Inc.'s eps (diluted) ranks #67 of 204 in the Health Care sector. Declined from $-0.45 to $-0.47 over the past 2 years.
Based on SEC 10-K filings.
-0.47 in FY2024.
Declined from $-0.45 to $-0.47 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#67 of 204 in Health CareTop 33% of 204This company -$0.47 Sector average -$0.89
▼
+47.0% above sector average
Key checks
Key Insights
- In FY2024, eps (diluted) decreased 62.1% year-over-year.
- Ranks #67 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.47 | -62.1% |
| FY2023 | -$0.29 | +35.6% |
| FY2022 | -$0.45 | +69.8% |
| FY2021 | -$1.49 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026